七味白术散加减辅助治疗84例2型糖尿病的疗效分析

目的：分析2型糖尿病采用七味白术散加减辅助治疗的临床疗效和安全性。方法：采用随机数字表法将167例2型糖尿病患者分为两组，对照组予磺脲类、双胍类等降糖药或者联合胰岛素治疗，观察组在对照组基础上予七味白术散加减治疗，对比60d后空腹血糖、餐后血糖、糖化血红蛋白指标和药物安全性。结果：两组均能够降低治疗后生化指标，但观察组降低治疗后生化指标幅度明显高于对照组，P〈0.05；观察组总有效率为96.43%，明显高于对照组87.95%，P〈0.05；观察组不良反应发生率为2.38%，明显低于对照组10.84%，P〈0.05。结论：七味白术散辅助治疗2型糖尿病疗效确切，能够通过多途径、多靶点发挥降血糖作用，而且可保护胰腺功能，不良反应少，建议临床继续探讨和推广。

An effective analysis of treating 84 cases of diabetes II with Qiwei Baizhu San

Objective： To analyze clinical efficacy and safety of Qiwei Baizhu San on diabetes II. Methods： 167 patients with diabetes II were randomly divided into the control group and the observation group. The control group was given sulfonylureas, biguanides, or plus insulin; another was given Qiwei Baizhu San more. FPG in 60d, PBG, glycated hemoglobin index and safety of drugs were compared. Results：The two groups could decrease biochemical indexes after treatment, but the observation group was better （P〈0.05）;the total efficacy in the observation was 96.43%, obviously higher than 87.95%in the control （P〈0.05）; the rate of adverse reactions in the observation was 2.38%, obviously lower than 10.84%in the control （P〈0.05）. Conclusion：Qiwei Baizhu San showed good clinical efficacy, could reduce blood sugar through multi-paths and multi-targets, protect pancreatic function, with less adverse reactions, and was worthy of promotion.